Natriumbikarbonat Abboxia: Uses, Dosage & Side Effects
A sodium bicarbonate infusion solution (50 mg/ml) used for the correction of metabolic acidosis, urinary alkalinization, and as a buffering agent in critical care settings
Natriumbikarbonat Abboxia is a sterile sodium bicarbonate infusion solution containing 50 mg/ml of sodium bicarbonate (NaHCO3). It is a systemic alkalinizing agent used primarily in hospital and critical care settings for the correction of metabolic acidosis. This medication is administered intravenously under close medical supervision and is indicated when the blood pH drops below safe levels due to conditions such as severe lactic acidosis, diabetic ketoacidosis, renal failure, cardiac arrest, or certain drug intoxications. Sodium bicarbonate is listed on the WHO Model List of Essential Medicines and is a fundamental component of emergency and critical care pharmacotherapy worldwide.
Quick Facts: Natriumbikarbonat Abboxia
Key Takeaways
- Natriumbikarbonat Abboxia is a sodium bicarbonate infusion solution (50 mg/ml) used to correct metabolic acidosis by directly buffering excess hydrogen ions in the blood and raising blood pH toward normal levels.
- This medication must be administered intravenously in a hospital or clinical setting under close medical supervision with continuous monitoring of arterial blood gases, serum electrolytes, and fluid balance.
- Common clinical indications include severe metabolic acidosis from lactic acidosis, diabetic ketoacidosis (adjunctive therapy), renal tubular acidosis, cardiac arrest, and certain drug intoxications requiring urinary alkalinization.
- Overcorrection with sodium bicarbonate can cause metabolic alkalosis, hypokalemia, hypernatremia, hyperosmolality, and paradoxical intracellular acidosis, making careful dose titration essential.
- Sodium bicarbonate interacts with numerous medications by altering urinary pH, which can affect drug elimination rates; concomitant medications must be carefully reviewed before and during administration.
What Is Natriumbikarbonat Abboxia and What Is It Used For?
Sodium bicarbonate is one of the most important buffering agents used in clinical medicine. The human body maintains blood pH within a narrow range of 7.35 to 7.45 through a complex system of buffers, the most significant of which is the bicarbonate-carbonic acid system. When this system is overwhelmed by excess acid production, impaired acid excretion, or bicarbonate losses, the result is metabolic acidosis—a potentially life-threatening condition that requires prompt medical intervention.
Natriumbikarbonat Abboxia provides exogenous sodium bicarbonate directly into the bloodstream via intravenous infusion. Once in the blood, the bicarbonate ion (HCO3−) combines with excess hydrogen ions (H+) to form carbonic acid (H2CO3), which rapidly dissociates into water (H2O) and carbon dioxide (CO2). The carbon dioxide is then eliminated through the lungs via normal respiratory function. This elegant biochemical process effectively removes acid from the body and restores the blood pH toward its normal physiological range.
The medication is classified under ATC code B05BB01 (electrolytes with sodium bicarbonate) and is listed on the World Health Organization (WHO) Model List of Essential Medicines, reflecting its fundamental role in emergency and critical care medicine worldwide. Sodium bicarbonate infusion solutions are used in virtually every hospital and critical care unit globally, making it one of the most widely available and universally recognized therapeutic agents in medicine.
The primary indications for Natriumbikarbonat Abboxia include:
- Severe metabolic acidosis: Correction of documented metabolic acidosis when the arterial blood pH falls below 7.1–7.2, or when bicarbonate levels are critically low, regardless of the underlying cause. This may occur in conditions such as sepsis, shock, severe dehydration, or prolonged tissue hypoxia.
- Lactic acidosis: As an adjunctive treatment when lactic acid accumulates due to tissue hypoperfusion, severe exercise, liver failure, or mitochondrial dysfunction. The primary treatment remains addressing the underlying cause, but bicarbonate may be needed when acidosis is life-threatening.
- Diabetic ketoacidosis (DKA): Used as adjunctive therapy in severe cases of DKA when the pH drops below 6.9–7.0, although insulin and fluid replacement remain the cornerstone treatments. Current guidelines recommend cautious use of bicarbonate in DKA due to potential complications.
- Renal tubular acidosis: For patients with type 1 (distal) or type 2 (proximal) renal tubular acidosis who are unable to maintain adequate bicarbonate levels through oral supplementation alone, particularly during acute exacerbations or when oral intake is not possible.
- Cardiac arrest: In select circumstances during cardiopulmonary resuscitation, particularly when pre-existing metabolic acidosis, hyperkalemia, or tricyclic antidepressant overdose is present. Routine use in cardiac arrest is not recommended by current American Heart Association (AHA) or European Resuscitation Council (ERC) guidelines.
- Urinary alkalinization: To raise urinary pH in order to enhance the renal excretion of certain drugs or toxins, such as salicylates (aspirin overdose), methotrexate, or barbiturates. Alkaline urine promotes ionization of these weak acids, trapping them in the renal tubular lumen and preventing reabsorption.
- Hyperkalemia: As a temporizing measure to shift potassium from the extracellular space into cells by raising blood pH, providing a short-term reduction in serum potassium levels while definitive treatment is arranged.
Sodium bicarbonate is included on the WHO Model List of Essential Medicines (2023 edition), underscoring its critical importance in healthcare systems worldwide. It is considered a basic and indispensable medication for any functioning healthcare facility, particularly in emergency departments and intensive care units.
What Should You Know Before Receiving Natriumbikarbonat Abboxia?
Before administering sodium bicarbonate infusion, healthcare providers must thoroughly assess the patient’s clinical condition, review relevant laboratory values, and identify any contraindications or risk factors that may influence the safety and efficacy of treatment. This medication is never self-administered and is always given under the direct supervision of qualified medical personnel in a hospital or clinical setting.
Contraindications
Natriumbikarbonat Abboxia must not be used in the following situations:
- Metabolic alkalosis: When the blood pH is already elevated above the normal range (pH > 7.45), administration of additional bicarbonate would worsen the alkalotic state and could lead to dangerous cardiac arrhythmias, seizures, or death.
- Respiratory alkalosis: In patients with excessive ventilation (hyperventilation) leading to low carbon dioxide levels and elevated blood pH, sodium bicarbonate is contraindicated because the underlying problem is respiratory, not metabolic.
- Severe hypernatremia: Since sodium bicarbonate contains sodium ions, administration in patients with already elevated serum sodium levels could exacerbate hypernatremia and its associated neurological complications.
- Hypocalcemia: Alkalinization of the blood reduces the concentration of ionized (active) calcium. In patients with pre-existing hypocalcemia, this reduction can precipitate tetany, cardiac arrhythmias, or seizures.
- Hypochloremic alkalosis: Conditions causing chloride-responsive alkalosis, such as prolonged vomiting or nasogastric suction, should be treated with chloride-containing solutions rather than bicarbonate.
Warnings and Precautions
Healthcare providers should exercise particular caution when administering sodium bicarbonate in the following clinical scenarios. Each of these situations requires careful risk-benefit assessment and heightened monitoring:
- Heart failure and fluid overload: The sodium content of sodium bicarbonate infusion can exacerbate fluid retention and worsen congestive heart failure. Each milliliter of Natriumbikarbonat Abboxia 50 mg/ml contains approximately 0.6 mmol of sodium, and large volumes can deliver a significant sodium load. Patients with heart failure, volume overload, or edema require particularly careful volume management and may benefit from slower infusion rates or more concentrated formulations.
- Renal impairment: Patients with reduced kidney function may have impaired ability to excrete the sodium and bicarbonate load, increasing the risk of hypernatremia, fluid retention, and metabolic alkalosis. Dose reduction and more frequent monitoring of serum electrolytes and fluid balance are essential.
- Hypertension: The sodium load associated with bicarbonate infusion can raise blood pressure. In patients with pre-existing hypertension, careful monitoring of blood pressure during and after administration is recommended.
- Hypokalemia risk: Correction of acidosis causes potassium to shift from the extracellular space back into cells, which can precipitate or worsen hypokalemia. Serum potassium levels must be monitored closely, and potassium supplementation may be necessary before or during bicarbonate therapy.
- Paradoxical intracellular acidosis: While sodium bicarbonate raises extracellular pH, the carbon dioxide generated during buffering can diffuse rapidly across cell membranes and into cells, where it reforms carbonic acid and actually lowers intracellular pH. This phenomenon is particularly relevant in patients with impaired ventilation who cannot adequately eliminate CO2.
- Extravasation: Natriumbikarbonat Abboxia 50 mg/ml is a hypertonic solution. If it leaks from the vein into surrounding tissues (extravasation), it can cause chemical cellulitis, tissue necrosis, ulceration, and skin sloughing. The infusion site must be monitored continuously, and administration should be through a large-bore vein or central venous catheter when possible.
Pregnancy and Breastfeeding
There is limited clinical data on the use of intravenous sodium bicarbonate during pregnancy. Sodium bicarbonate should be used during pregnancy only when clearly necessary and when the potential benefit justifies the potential risk to the mother and fetus. The sodium load may contribute to fluid retention and edema, which can be of particular concern during pregnancy. In situations where severe metabolic acidosis threatens the life of the mother, the benefit of treatment typically outweighs the potential risks.
Sodium and bicarbonate are natural components of human milk and blood. While intravenous administration may transiently increase maternal sodium and bicarbonate levels, there is no evidence suggesting that this poses a significant risk to the breastfed infant. Nevertheless, the decision to administer sodium bicarbonate to a breastfeeding mother should be made in consultation with a specialist physician who can assess the clinical situation.
Rapid intravenous administration of sodium bicarbonate to neonates and infants under 2 years of age has been associated with intraventricular hemorrhage (bleeding in the brain). In neonatal patients, sodium bicarbonate must be administered as a slow infusion over at least 30 minutes, using a diluted solution, and only when absolutely necessary. The osmolality of concentrated sodium bicarbonate solutions is very high and can be harmful to the immature neonatal brain vasculature.
How Does Natriumbikarbonat Abboxia Interact with Other Drugs?
Sodium bicarbonate has a broad interaction profile because it alters both blood pH and urinary pH, which can significantly affect the pharmacokinetics of many drugs. These interactions are clinically important and must be considered by the healthcare team managing the patient. Additionally, sodium bicarbonate solutions can be chemically incompatible with many other intravenous drugs and solutions, leading to precipitation, inactivation, or degradation of one or both agents.
Major Interactions
| Drug / Class | Type of Interaction | Clinical Significance |
|---|---|---|
| Lithium | Increased renal excretion of lithium due to urinary alkalinization | May reduce lithium levels below therapeutic range, risking loss of mood stabilization. Monitor lithium levels closely. |
| Methotrexate | Urinary alkalinization increases methotrexate solubility and excretion | Intentionally used in high-dose methotrexate protocols to prevent nephrotoxicity from crystal precipitation in renal tubules. |
| Salicylates (Aspirin) | Enhanced renal excretion through ion trapping in alkaline urine | Therapeutically used in salicylate overdose to accelerate drug elimination. Monitor salicylate levels and urine pH. |
| Sympathomimetics (Ephedrine, Pseudoephedrine) | Decreased renal excretion due to urinary alkalinization | May increase plasma levels and duration of action of sympathomimetic amines, potentially causing hypertension or tachycardia. |
| Amphetamines | Decreased renal excretion in alkaline urine | Alkaline urine significantly prolongs half-life and increases drug effect. Risk of toxicity with prolonged bicarbonate use. |
| Quinidine | Reduced renal clearance in alkaline urine | Elevated quinidine levels increase risk of cardiac arrhythmias and QT prolongation. Monitor ECG and drug levels. |
Minor Interactions
| Drug / Class | Effect | Management |
|---|---|---|
| Tetracyclines | Reduced absorption and efficacy due to chelation in alkaline environment | Avoid concomitant administration if possible; separate timing. |
| Iron preparations | Decreased iron absorption in alkaline gastrointestinal environment | Primarily relevant for oral bicarbonate; less significant with IV route. |
| Corticosteroids | Additive sodium and fluid retention | Monitor fluid balance, weight, and blood pressure closely. |
| Potassium-wasting diuretics | Additive hypokalemia risk | Monitor serum potassium frequently and supplement as needed. |
| Calcium-containing solutions | Precipitation of calcium carbonate when mixed | Never mix in the same IV line. Flush line between infusions. |
In addition to pharmacokinetic interactions, sodium bicarbonate solutions are physically and chemically incompatible with many intravenous drugs. As a strongly alkaline solution, it can cause precipitation, degradation, or inactivation of various medications when mixed in the same infusion line. Healthcare professionals should always consult compatibility references before co-administering any intravenous medication with sodium bicarbonate, and should use a dedicated intravenous line whenever possible.
Sodium bicarbonate solution is incompatible with many common intravenous medications including catecholamines (dopamine, dobutamine, norepinephrine), calcium salts, magnesium sulfate, and numerous antibiotics. Always use a separate IV line for sodium bicarbonate infusion or flush the line thoroughly between different medications.
What Is the Correct Dosage of Natriumbikarbonat Abboxia?
The dosing of sodium bicarbonate infusion is fundamentally different from most other medications because it must be individualized to each patient based on their specific acid-base status. There is no single “standard dose” that applies to all patients. Instead, the dose is calculated from the patient’s measured blood gas values and is then adjusted based on the clinical response. The goal is to raise the blood pH to a safe level (typically above 7.20) without overcorrecting into alkalosis.
The bicarbonate deficit can be estimated using the following formula:
HCO3− deficit (mEq) = 0.5 × body weight (kg) × (24 − measured serum HCO3−)
Where 24 mEq/L is the target serum bicarbonate level and 0.5 represents the approximate volume of distribution of bicarbonate (50% of body weight). Generally, only 50% of the calculated deficit is administered initially, with reassessment of blood gases before further dosing.
Adults
Metabolic Acidosis (General)
Initial dose: 50–150 mEq (approximately 50–150 ml of 50 mg/ml solution) by slow intravenous infusion over 30–60 minutes. Repeat arterial blood gas measurement after 30 minutes and adjust subsequent doses accordingly. Aim to correct pH to 7.20–7.25 initially, not to normal values, to avoid overcorrection. The total dose over 24 hours rarely exceeds 200–400 mEq in most clinical scenarios.
Cardiac Arrest
Initial dose: 1 mEq/kg (approximately 1 ml/kg of 50 mg/ml solution) by rapid intravenous injection. Subsequent doses of 0.5 mEq/kg may be given every 10 minutes during continued resuscitation, guided by blood gas results when available. Routine use in cardiac arrest is not recommended by current guidelines unless specific indications are present (pre-existing metabolic acidosis, hyperkalemia, or tricyclic antidepressant overdose).
Urinary Alkalinization
Continuous infusion: 150 mEq sodium bicarbonate added to 1 liter of 5% dextrose in water, infused at 150–200 ml/hour. Target urine pH: 7.5–8.0. Monitor urine pH every 1–2 hours and adjust infusion rate accordingly. Maintain adequate urine output (>2 ml/kg/hour) during alkalinization therapy.
Children
Pediatric Metabolic Acidosis
Children (over 2 years): 1–2 mEq/kg by slow intravenous infusion over 30–60 minutes. Subsequent doses based on blood gas results. Maximum rate: 1 mEq/kg/hour. For neonates and infants under 2 years, use a diluted solution (no greater than 4.2% or 0.5 mEq/ml) administered very slowly over at least 30 minutes to minimize the risk of intraventricular hemorrhage. Neonatal dose: 1–2 mEq/kg by slow infusion.
Elderly
Geriatric Dosing Considerations
Elderly patients often have reduced renal function, decreased cardiac reserve, and may be on sodium-restricted diets. Start with lower doses, infuse more slowly, and monitor more frequently. The sodium load may be poorly tolerated in patients with age-related cardiac or renal dysfunction. Careful attention to fluid balance is essential, as the elderly are at increased risk of fluid overload and pulmonary edema.
Missed Dose
Natriumbikarbonat Abboxia is administered in a hospital setting by healthcare professionals as a monitored infusion. The concept of a “missed dose” does not apply in the traditional sense. Dosing is guided by real-time blood gas results, and the timing and amount of each administration are determined by the treating physician based on the patient’s evolving clinical status. If an infusion is interrupted, the decision to resume or modify dosing is made based on current laboratory values.
Overdose
Overdose of sodium bicarbonate, whether from excessive dosing or rapid administration, can result in serious and potentially life-threatening complications. The most significant risks include:
- Metabolic alkalosis: Overcorrection of blood pH above 7.55 can cause cardiac arrhythmias, impaired oxygen delivery to tissues (leftward shift of the oxygen-hemoglobin dissociation curve), confusion, seizures, and potentially death.
- Hypernatremia: Excessive sodium loading can cause severe elevation of serum sodium, leading to cellular dehydration, neurological dysfunction, seizures, and in extreme cases, osmotic demyelination syndrome.
- Hypokalemia: Alkalosis drives potassium into cells, potentially causing life-threatening hypokalemia with cardiac arrhythmias, muscle weakness, and respiratory failure.
- Hyperosmolality: The high sodium content can elevate serum osmolality, causing cellular dehydration and neurological complications.
- Fluid overload: Large volumes of infusion can cause pulmonary edema, particularly in patients with compromised cardiac or renal function.
Treatment of sodium bicarbonate overdose is supportive and directed at correcting the resulting metabolic derangements. This may include administration of potassium chloride for hypokalemia, isotonic or hypotonic saline for hypernatremia, and in severe cases of alkalosis, administration of ammonium chloride or hydrochloric acid under specialist guidance. Hemodialysis may be necessary in patients with renal failure who cannot excrete the excess sodium and bicarbonate.
If sodium bicarbonate overdose is suspected, discontinue the infusion immediately. Obtain urgent arterial blood gas, serum electrolytes (especially potassium, sodium, calcium), and serum osmolality. Severe metabolic alkalosis (pH > 7.55) is a medical emergency requiring immediate intensive care management. Contact the local poison control center or critical care specialist for guidance.
What Are the Side Effects of Natriumbikarbonat Abboxia?
The side effects of sodium bicarbonate infusion are primarily extensions of its pharmacological action. Because it directly affects acid-base balance and electrolyte concentrations, the most common adverse effects are metabolic in nature. The risk and severity of side effects are closely related to the dose administered, the rate of infusion, and the patient’s underlying clinical condition, particularly their renal and cardiovascular function.
It is important to understand that many of these effects are predictable and manageable with appropriate monitoring. Healthcare professionals administering sodium bicarbonate infusion are trained to anticipate and manage these complications, which is why this medication is only given in supervised clinical settings with access to laboratory monitoring and intensive care facilities.
Very Common (may affect more than 1 in 10 patients)
- Metabolic alkalosis (overcorrection of pH beyond normal range)
- Hypokalemia (decreased serum potassium levels)
- Hypernatremia (elevated serum sodium levels)
- Fluid retention and peripheral edema
- Increased carbon dioxide production (requiring adequate ventilation)
Common (may affect up to 1 in 10 patients)
- Venous irritation and pain at the infusion site
- Hypocalcemia (reduced ionized calcium due to alkalosis)
- Abdominal distension and bloating
- Thirst and dry mouth
- Headache
- Nausea
Uncommon (may affect up to 1 in 100 patients)
- Hyperosmolality
- Muscle twitching or tetany (from hypocalcemia)
- Hypertension (from sodium and fluid loading)
- Tissue necrosis from extravasation
- Chemical cellulitis at infusion site
Rare (may affect fewer than 1 in 1,000 patients)
- Intraventricular hemorrhage (primarily in neonates with rapid administration)
- Cardiac arrhythmias (from severe alkalosis or electrolyte disturbances)
- Seizures (from severe alkalosis or hypocalcemia)
- Paradoxical CNS acidosis
- Pulmonary edema (from fluid overload)
Patients who are receiving sodium bicarbonate infusion in the hospital setting are typically critically ill and may experience symptoms related to their underlying condition rather than the medication itself. Healthcare providers differentiate between medication-related adverse effects and disease-related symptoms through careful clinical assessment and laboratory monitoring.
If you are a patient or family member and notice any unusual symptoms during sodium bicarbonate infusion, immediately inform the nursing or medical staff. Most side effects are manageable when detected early, and prompt dose adjustment or discontinuation can prevent serious complications.
Healthcare professionals and patients can report suspected adverse reactions through national pharmacovigilance systems. In the EU, reports can be submitted through the national competent authority or via the EMA’s EudraVigilance system. In the US, adverse events can be reported to the FDA MedWatch program. Reporting helps improve the safety knowledge base for all medicines.
How Should You Store Natriumbikarbonat Abboxia?
Proper storage of sodium bicarbonate infusion solution is essential to maintain its safety, sterility, and efficacy. As a hospital-administered medication, storage is managed by pharmacy and nursing staff according to established protocols. However, understanding storage requirements is important for all healthcare professionals involved in the medication’s handling and administration.
- Temperature: Store at room temperature, typically between 15°C and 25°C (59°F to 77°F). Do not expose to extreme heat or freezing temperatures. Freezing can cause container damage and compromise sterility.
- Light protection: Keep in the outer carton to protect from light until ready for use. Prolonged exposure to light may degrade the solution over time.
- Visual inspection: Before administration, the solution must be visually inspected. It should be clear, colorless, and free from visible particles. Do not use if the solution is cloudy, contains precipitate, or if the container seal is compromised.
- Single use: Natriumbikarbonat Abboxia infusion solution is for single use only. Once the container has been opened or pierced, the contents must be used immediately. Any unused solution remaining after use must be discarded in accordance with local protocols for pharmaceutical waste.
- Do not mix: Do not add other medications or additives to the sodium bicarbonate infusion bag or bottle unless compatibility has been verified. Chemical incompatibility can lead to precipitation or inactivation of one or both agents.
- Shelf life: Check the expiry date on the packaging before use. Do not use the product after the stated expiry date. Expired solutions may have altered pH, osmolality, or sterility and must be disposed of properly.
Keep all medicines out of the reach of children. Do not dispose of medicines in household waste or wastewater. Healthcare facilities should follow local regulations for the disposal of unused pharmaceutical products to minimize environmental impact.
What Does Natriumbikarbonat Abboxia Contain?
Understanding the composition of Natriumbikarbonat Abboxia is important for healthcare professionals who are calculating doses, assessing the patient’s total sodium and fluid intake, and evaluating compatibility with other intravenous solutions and medications.
Active Ingredient
- Sodium bicarbonate (NaHCO3): 50 mg per ml (5% w/v solution), equivalent to approximately 0.595 mmol/ml of sodium and 0.595 mmol/ml of bicarbonate. The molecular weight of sodium bicarbonate is 84.01 g/mol.
Excipients
- Water for injections: Pharmaceutical-grade purified water serving as the solvent. Compliant with pharmacopoeia standards for parenteral preparations.
- Carbon dioxide (E290): May be present in small amounts as a result of the equilibrium between sodium bicarbonate and carbonic acid in aqueous solution. The solution pH is typically in the range of 7.0–8.5.
Key Physicochemical Properties
| Property | Value |
|---|---|
| Concentration | 50 mg/ml (5% w/v) |
| Sodium content | Approximately 0.6 mmol/ml (595 mmol/L) |
| Bicarbonate content | Approximately 0.6 mmol/ml (595 mmol/L) |
| Theoretical osmolality | Approximately 1,190 mOsmol/kg (hypertonic) |
| pH | 7.0–8.5 |
| Appearance | Clear, colorless solution |
The hypertonic nature of this solution (approximately 4 times the osmolality of blood) is an important clinical consideration. Administration through a peripheral vein carries a risk of venous irritation and extravasation injury. When large volumes or prolonged infusions are required, administration through a central venous catheter is preferred to minimize these risks. In some clinical situations, the solution may be diluted with sterile water for injection or 5% dextrose to reduce osmolality before administration, particularly in neonates and pediatric patients.
Frequently Asked Questions
Sodium bicarbonate is available in both intravenous (IV) infusion and oral tablet/powder forms, but they serve different clinical purposes. The IV infusion form (such as Natriumbikarbonat Abboxia) is used in hospitals for acute, severe metabolic acidosis where rapid correction of blood pH is needed. It delivers bicarbonate directly into the bloodstream with immediate effect. Oral sodium bicarbonate tablets or powder are used for milder, chronic conditions such as chronic kidney disease-related acidosis or as an antacid for heartburn. Oral forms are absorbed through the gastrointestinal tract, have a slower onset, and are suitable for outpatient use. The IV formulation should never be used outside of a supervised medical setting.
While sodium bicarbonate was historically administered routinely during cardiac arrest, current evidence and guidelines from the American Heart Association (AHA) and European Resuscitation Council (ERC) no longer recommend routine use. The primary reason is that the CO2 generated by the bicarbonate buffering reaction can diffuse into cells faster than bicarbonate, paradoxically worsening intracellular acidosis. Additionally, effective chest compressions and ventilation are more important for managing acidosis during cardiac arrest, as they restore circulation and CO2 elimination. Sodium bicarbonate is still recommended in specific situations: pre-existing metabolic acidosis, hyperkalemia, or tricyclic antidepressant overdose during cardiac arrest.
Yes, hypokalemia (low potassium) is one of the most common and clinically significant side effects of sodium bicarbonate infusion. When the blood pH rises (becomes more alkaline) after bicarbonate administration, hydrogen ions move from inside cells into the blood to help buffer the pH change. To maintain electrical neutrality, potassium ions move in the opposite direction—from the blood into cells. This transcellular shift reduces serum potassium levels, sometimes dramatically. For every 0.1 unit increase in blood pH, serum potassium may decrease by approximately 0.3–0.5 mEq/L. This is why serum potassium must be measured before and frequently during bicarbonate therapy, and potassium supplementation may be needed to prevent dangerous hypokalemia.
The rate of sodium bicarbonate infusion depends on the clinical urgency and patient population. In adults with non-life-threatening metabolic acidosis, the infusion should be given slowly over 30–60 minutes or longer, with frequent blood gas monitoring to guide the rate. In cardiac arrest, a bolus of 1 mEq/kg may be given by rapid IV injection. In neonates and infants under 2 years, the maximum infusion rate should not exceed 10 mEq/kg/day, and each dose should be infused over at least 30 minutes to prevent intraventricular hemorrhage. In all cases, the principle of “go slow, check often” applies—overcorrection is difficult to reverse and can be more dangerous than the acidosis itself.
Extravasation of sodium bicarbonate infusion is a serious complication because the solution is hypertonic (much more concentrated than body fluids). When the hypertonic solution leaks into surrounding tissues, it draws fluid out of cells through osmosis, causing cellular dehydration and potentially leading to chemical cellulitis, tissue necrosis, ulceration, and skin sloughing. If extravasation is suspected, the infusion must be stopped immediately. The affected area should be elevated and cold compresses applied. Depending on the severity, surgical consultation may be necessary. To minimize the risk of extravasation, sodium bicarbonate should ideally be administered through a central venous catheter, especially when large volumes or prolonged infusions are needed.
All information in this article is based on international medical guidelines and peer-reviewed research: the WHO Model List of Essential Medicines (2023), AHA Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care (2020), Surviving Sepsis Campaign International Guidelines (2021), British National Formulary (BNF) drug monographs, European Medicines Agency (EMA) product information, and peer-reviewed literature on acid-base physiology and critical care pharmacotherapy. All medical claims are supported by evidence at the highest available level according to the GRADE evidence framework.
References
- World Health Organization. WHO Model List of Essential Medicines – 23rd List (2023). Geneva: WHO; 2023.
- Panchal AR, Bartos JA, Cabañas JG, et al. Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2020;142(16_suppl_2):S366–S468.
- Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Intensive Care Med. 2021;47(11):1181–1247.
- Joint Formulary Committee. British National Formulary (BNF) 86. London: BMJ Group and Pharmaceutical Press; 2025. Sodium Bicarbonate Monograph.
- Berend K, de Vries APJ, Gans ROB. Physiological approach to assessment of acid-base disturbances. N Engl J Med. 2014;371(15):1434–1445.
- Jaber S, Paugam C, Futier E, et al. Sodium bicarbonate therapy for patients with severe metabolic acidaemia in the intensive care unit (BICAR-ICU): a multicentre, open-label, randomised controlled, phase 3 trial. Lancet. 2018;392(10141):31–40.
- Velissaris D, Karamouzos V, Ktenopoulos N, et al. The Use of Sodium Bicarbonate in the Treatment of Acidosis in Sepsis: A Literature Update on a Long Term Debate. Crit Care Res Pract. 2015;2015:605830.
- Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32(7):1335–1343.
- European Resuscitation Council. European Resuscitation Council Guidelines 2021: Adult advanced life support. Resuscitation. 2021;161:115–151.
- Kraut JA, Madias NE. Metabolic acidosis: pathophysiology, diagnosis and management. Nat Rev Nephrol. 2010;6(5):274–285.
Medical Editorial Team
This article has been reviewed by qualified medical professionals to ensure clinical accuracy and adherence to international medical guidelines.
Critical Care Medicine Specialist
Board-certified intensivist with expertise in acid-base physiology, hemodynamic management, and critical care pharmacotherapy.
Clinical Pharmacologist
Specialist in drug interactions, pharmacokinetics, and medication safety in the intensive care setting.
Emergency Medicine Physician
Experienced in acute resuscitation, metabolic emergencies, and point-of-care acid-base assessment.
Medical Editor
Ensures content accuracy, readability, and compliance with health literacy standards and WCAG accessibility guidelines.
Editorial Process: All content follows the iMedic Editorial Standards, including peer review by specialist physicians, fact-checking against primary sources, and regular updates to reflect current clinical guidelines. Our editorial team has no conflicts of interest and receives no pharmaceutical industry funding.